Study #2023-1010
A randomized, double-blind, multi-center, phase III study of AK112 or Placebo combined with Pemetrexed and Carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment
MD Anderson Study Status
Not Accepting
Treatment Agent
AK112 Injection, Placebo Injection
Description
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Squamous Non-small Cell Lung Cancer
Study phase:
Phase III
Physician name:
Xiuning Le
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-401-1031
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.